Shows & Panels
Shows & Panels
- The 2014 Big Picture on Cyber Security
- AFCEA Answers
- American Readiness: Renewable Power and Efficiency Technologies
- Ask the CIO
- Building the Hybrid Cloud
- Connected Government: How to Build and Procure Network Services for the Future
- Continuing Diagnostics and Mitigation: Discussion of Progress and Next Steps
- Federal Executive Forum
- Federal News Radio's National Cyber Security Awareness Month Special Panel Discussion
- Federal Tech Talk
- The Future of Government Data Centers
- The Future of IT: How CIOs Can Enable the Service-Oriented Enterprise
- Government Perspectives on Mobility and the Cloud
- The Intersection: Where Technology Meets Transformation
- Maximizing ROI Through Data Center Consolidation
- Mitigating Insider Threats in Virtual & Cloud Environments
- Modern Mission Critical Series
- The New Generation of Database
- Reimagining the Next Generation of Government
- Targeting Advanced Threats: Proven Methods from Detection through Remediation
- Transformative Technology: Desktop Virtualization in Government
- The Truth About IT Opex and Software Defined Networking
- Air Traffic Management Transformation Report
- Cloud First Report
- General Dynamics IT Enterprise Center
- Gov Cloud Minute
- Government in Technology Series
- Homeland Security Cybersecurity Market Report
- National Cybersecurity Awareness Month
- Technology Insights
- The Cyber Security Report
- The Next Generation Cyber Security Experts
Shows & Panels
US adviser on board of firm that sold anthrax drug
Monday - 5/20/2013, 11:08am EDT
WASHINGTON (AP) -- Former Navy Secretary Richard J. Danzig, who has served as a bio-warfare adviser to the president, the Pentagon, and the Department of Homeland Security, urged the government to stockpile an anti-anthrax drug while serving as a director for the company that supplied it, according to a report published Sunday.
While there is no evidence any nation or terrorist group has achieved it, Danzig warned for a decade that terrorists could easily engineer a strain of anthrax resistant to common antibiotics that could be a devastating threat to national security, according to an investigation by the Los Angeles Times (http://lat.ms/12K6Rxh ).
Danzig successfully suggested stockpiling a drug known as raxibacumab, or "raxi," to guard against the potential threat, and biotech startup Human Genome Sciences Inc. has won $334 million in federal contracts since 2006 to supply the drug that now goes for $5,100 a dose.
At the same time, Danzig was a director for the company, earning more than $1 million in company compensation between 2001 and 2012. It was the first product the company sold and the U.S. government remains the only buyer. The Rockville, Md.-based company was acquired by GlaxoSmithKline in August for $3.6 billion.
Several officials who attended seminars led by Danzig said they had no knowledge of his ties to Human Genome Sciences.
"Holy smoke -- that was a horrible conflict of interest," said Dr. Philip K. Russell, a physician, retired major-general and biodefense official in the George W. Bush administration.
Federal law bars U.S. officials, including advisers and consultants, from giving counsel on matters in which they have a financial interest.
Danzig said there was no conflict of interest, and that he sought only to inform officials of the danger, not to lobby for the purchase of raxibacumab.
"My view was I'm not going to get involved in selling that," Danzig told the Times in an interview. "But at the same time now, should I not say what I think is right in the government circles with regard to this?"
Danzig added, "I feel that I've acted very properly with regard to this."
Danzig, 68, who served as Navy secretary in the Clinton administration and has since worked as a consultant, began warning about antibiotic-resistant anthrax in the wake of five deaths from anthrax-laced letters that came soon after the terrorist attacks of Sept. 11, 2001.
The anthrax in the letters was not resistant to antibiotics, but Danzig was soon warning of the possibility of a deadlier form of the germ, saying his interest in the subject came from "people whose technical skills exceed mine."
The Times investigation found seven papers Danzig had written on bioterrorism since 2001, and in only one did he disclose his ties to Human Genome Sciences.
Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.